| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 8733663 | Critical Reviews in Oncology/Hematology | 2018 | 10 Pages |
Abstract
For the first time, our meta-analysis provides evidence that efficacy of anti-EGFR based treatments could be dependent on both p16 status and treatment modality. p16 status is likely to have a role in predicting survival to anti-EGFR based treatments in recurrent or metastatic HNSCC.
Related Topics
Health Sciences
Medicine and Dentistry
Hematology
Authors
Yapin Su, Jiuwei Cui, Dongsheng Xu, Mengmeng Wang, Tiankai Xu, Huimn Tian, Fujun Han,